With the FerroTACs in hand, and the proposed conformational bias established, we proceeded to systematically evaluate their degradation profiles in cellular contexts. To determine the cellular potency of the VHL-targeting homo-FerroTACs, we conducted an initial screening by Western blot in HEK293 cells at two time points (4 h and 24 h) and concentrations (0.1 µM and 1 µM), employing CM11 and CMP98 as positive and negative controls for VHL degradation, respectively. In the initial screening (Figure ), degradation of the pVHL30 isoform induced by FerroTAC AS1a direct analogue of CM11was notably less effective than that of AS2 and its parent analogue. Specifically, AS1 achieved a maximal degradation (Dmax) of 48% for pVHL30 after 24 hours at 1 µM, compared to the 100% degradation observed with CM11 and AS2 under identical conditions (Figure ).